Skip to main content

Day: December 20, 2024

Hepsor AS financial calendar 2025

In 2025, Hepsor AS plans to disclose the consolidated financial results as follows:19 February 2025 Unaudited interim report for twelve months and Q4 202423 April 2025 Audited annual report for 202430 April 2025 Unaudited interim report for Q1 202530 July 2025 Unaudited interim report for six months and Q2 202529 October 2025 Unaudited interim report for nine months and Q3 2025Henri Laks Member of the Management Board Phone: +372 5693 9114 e-mail: henri@hepsor.ee – Hepsor AS (www.hepsor.ee) is a developer of residential and commercial real estate that operates in Estonia, Latvia, and from 2023 on the Canadian real estate market. Over the last thirteen years Hepsor has developed more than 2076 homes and 36,500 m2 of commercial space. Hepsor was the first real estate developer in the Baltic States to implement...

Continue reading

The Keg Royalties Income Fund announces January 2025 cash distribution

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its January 2025 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as of December 31, 2024. The January 2025 distribution will be paid on January 31, 2025. The record date for this distribution is earlier than in other months to coincide with the Fund’s year-end. Annually, two distributions are expected to be declared to the Fund’s unitholders during the first quarter, three distributions in each of the second and third quarters, and four distributions in the fourth quarter. This is done to ensure that the distribution based on the Royalty Pool sales for the month of December, in any year (which is paid the following month in January) is recorded in...

Continue reading

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection – – Highly experienced sales team already recruited and trained in preparation for commercial launch – DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is...

Continue reading

Gatos Silver Amends Joint Venture Agreements with Dowa to Obtain Enhanced Management Rights and Announces Financial Statement Consolidation

VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Gatos Silver, Inc. (NYSE/TSX: GATO) (“Gatos Silver” or the “Company”) today announced that it has entered into amended and restated agreements (the “Amended Agreements”) with Dowa Metals & Mining Co., Ltd. (“Dowa”) regarding the Los Gatos Joint Venture (the “LGJV”). The Amended Agreements, which are effective on January 1, 2025, expand Gatos Silver’s management rights within the LGJV which will result in the Company being able to fully consolidate the financial statements of the LGJV rather than accounting for its investment in the LGJV under the equity method of accounting as is currently required. The ownership interests of the Company and Dowa in the LGJV are unchanged, at 70% and 30%, respectively. The Amended Agreements strengthen Dowa’s zinc concentrate offtake...

Continue reading

Global Uranium Corp. Announces a C$1,000,000 Charity Flow Through Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTCQB: GURFF | FRA: Q3J) (the “Company“) is pleased to announce that it intends to complete a non-brokered charity flow-through private placement of common shares in the capital of the Company (“Shares”) at a price of $1 per Share for aggregate gross proceeds of up to C$1,000,000 (the “Offering”). The Shares issued under the Offering are intended to qualify as “flow through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act“). The gross proceeds from the sale of the Shares will be used to incur “Canadian exploration expenses” on the Company’s projects, including at the Northwest Athabasca Project, that are...

Continue reading

Osisko Development Announces Grant of Deferred Share Units

MONTREAL, Dec. 19, 2024 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) announces that it has granted 80,000 deferred share units (“DSUs“) of the Company to Mr. Stephen Quin, an independent director, as part of his recent appointment to the Company’s board of directors announced on December 5, 2024. The DSUs were granted in accordance with the Company’s DSU plan, which is available on the Company’s website at www.osiskodev.com. ABOUT OSISKO DEVELOPMENT CORP. Osisko Development Corp. is a North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company’s objective is to become an intermediate gold producer by advancing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.